PL442002A1 - Method of obtaining the second polymorphic form of itraconazole - Google Patents

Method of obtaining the second polymorphic form of itraconazole

Info

Publication number
PL442002A1
PL442002A1 PL442002A PL44200222A PL442002A1 PL 442002 A1 PL442002 A1 PL 442002A1 PL 442002 A PL442002 A PL 442002A PL 44200222 A PL44200222 A PL 44200222A PL 442002 A1 PL442002 A1 PL 442002A1
Authority
PL
Poland
Prior art keywords
temperature
range
polymorphic form
itraconazole
obtaining
Prior art date
Application number
PL442002A
Other languages
Polish (pl)
Other versions
PL248925B1 (en
Inventor
Marian Paluch
Justyna Knapik-Kowalczuk
Daniel Kramarczyk
Original Assignee
Uniwersytet Śląski W Katowicach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Śląski W Katowicach filed Critical Uniwersytet Śląski W Katowicach
Priority to PL442002A priority Critical patent/PL248925B1/en
Publication of PL442002A1 publication Critical patent/PL442002A1/en
Publication of PL248925B1 publication Critical patent/PL248925B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób otrzymania II (drugiej) formy polimorficznej itrakonazolu, polegający na wykrystalizowaniu materiału wyjściowego, to jest komercyjnie dostępnego materiału w I (pierwszej) odmianie polimorficznej, po uprzedniej zmianie uporządkowania jego formy nematycznej na skutek działania siły ścinającej. Sposób polega na tym, że materiał wyjściowy stanowiący itrakonazol (2-(butan-2-yl)-4-{4-[4-(4-{[2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one w krystalicznej I odmianie polimorficznej, przedstawiony strukturalnym wzorem 1, topi się, korzystnie w temperaturze od 439 do 483 K, następnie przechładza do temperatury z zakresu 298 - 364 K, po czym poddaje oscylacyjnemu ścinaniu w temperaturze z obszaru nematyka, to jest z zakresu 347 - 364 K, dla odkształceń (γ) z zakresu od 20 do 75%, korzystnie od 55 do 70%, aż do momentu zmiany uporządkowania molekuł materiału, to jest zmiany kierunku ich ułożenia z prostopadłego do równoległego do płaszczyzny okładek układu ścinającego, po czym wykrystalizowywuje się w temperaturze ≥ od temperatury pokojowej, najkorzystniej w temperaturze z obszaru cieczy izotropowej 364 < T < 439 K.The subject of the application is a method of obtaining the II (second) polymorphic form of itraconazole, consisting in crystallization of the starting material, i.e. commercially available material in the I (first) polymorphic form, after changing the order of its nematic form as a result of the action of shear force. The method is that the starting material itraconazole (2-(butan-2-yl)-4-{4-[4-(4-{[2R,4S)-2-(2,4-dichlorophenyl)-2 -(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1, 2,4-triazol-3-one in the crystalline polymorphic form I, represented by the structural formula 1, melts, preferably at a temperature from 439 to 483 K, then subcooled to a temperature in the range of 298 - 364 K, and then subjected to oscillatory shear at a temperature from the nematic range, i.e. in the range of 347 - 364 K, for strains (γ) in the range from 20 to 75%, preferably from 55 to 70%, until the arrangement of the material molecules changes, i.e. the direction of their arrangement changes from perpendicular to parallel to the plane of the plates of the shearing system, and then crystallizes at a temperature ≥ room temperature, most preferably at a temperature in the isotropic liquid region of 364 < T < 439 K.

PL442002A 2022-08-11 2022-08-11 Method of obtaining the second polymorphic form of itraconazole PL248925B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL442002A PL248925B1 (en) 2022-08-11 2022-08-11 Method of obtaining the second polymorphic form of itraconazole

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL442002A PL248925B1 (en) 2022-08-11 2022-08-11 Method of obtaining the second polymorphic form of itraconazole

Publications (2)

Publication Number Publication Date
PL442002A1 true PL442002A1 (en) 2024-02-12
PL248925B1 PL248925B1 (en) 2026-02-09

Family

ID=89855709

Family Applications (1)

Application Number Title Priority Date Filing Date
PL442002A PL248925B1 (en) 2022-08-11 2022-08-11 Method of obtaining the second polymorphic form of itraconazole

Country Status (1)

Country Link
PL (1) PL248925B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL447909A1 (en) * 2024-03-01 2025-09-08 Uniwersytet Śląski W Katowicach Method for obtaining itraconazole in a stable nematic phase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL447909A1 (en) * 2024-03-01 2025-09-08 Uniwersytet Śląski W Katowicach Method for obtaining itraconazole in a stable nematic phase

Also Published As

Publication number Publication date
PL248925B1 (en) 2026-02-09

Similar Documents

Publication Publication Date Title
ZA202207589B (en) Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
PL442002A1 (en) Method of obtaining the second polymorphic form of itraconazole
DE69835430T2 (en) Sulphonamide derivatives, their preparation and their use
RU2053230C1 (en) Method of synthesis of derivatives of aryl- or heteroarylpiperazinylbutylazole
CL2020002371A1 (en) Preparation process of two derivatives of 4 - {[(2s) -2- {4- [5-chloro-2- (1h-1,2,3-triazol-1-yl) phenyl] -5-methoxy-2 -oxpyridin-1 (2h) -yl} butanoyl] amino} -2-fluorobenzamide
SI2509955T1 (en) Pyrazole derivatives as modulators of calcium release-activated calcium channel
US4634770A (en) Isoquinolinesulfonamide derivatives
ES2225095T3 (en) UREA HEROCICLICA AND RELATED COMPOUNDS, USEFUL AS ANTI-INFLAMMATORY AGENTS.
JP2005510500A5 (en)
DE69519995T2 (en) APOLIPOPROTEIN-B SYNTHESIS INHIBITORS
Zencirci et al. Crystallization of metastable polymorphs of phenobarbital by isomorphic seeding
DK0424059T3 (en) Use of substituted imidazoles
WO2004069794B1 (en) New arylpiperazinyl compounds
RU2009117705A (en) 2-AMINOCARBONILPYRIDINE DERIVATIVES
Mehta et al. Accelerated physical stability testing of amorphous dispersions
Hadjipavlou‐Litina Review, reevaluation, and new results in quantitative structure‐activity studies of anticonvulsants
BR112020008848A2 (en) process of preparing large isoxazoline particles
JP2008546754A5 (en)
JP2007505031A5 (en)
US20040010147A1 (en) Cyclic amine compounds and pharmaceutical composition containing the same
JP3782455B2 (en) Novel triazolone as an apolipoprotein-B synthesis inhibitor
Kolek et al. Isothermal cold crystallization of antiferroelectric liquid crystal 3F5BFBiHex
JP2007532654A5 (en)
Cojocaru et al. Procainium acetate versus procainium acetate dihydrate: irreversible crystallization of a room-temperature Active Pharmaceutical-Ingredient ionic liquid upon hydration
Rasmussen et al. A versatile synthesis of novel N, N, N ″-trisubstituted guanidines